Correlation between gut microbiota and glucagon-like peptide-1 in patients with gestational diabetes mellitus

被引:19
|
作者
Liang, Yun-Yi [1 ]
Liu, Ling-Yu [2 ]
Jia, Yan [1 ]
Li, Yi [1 ,3 ]
Cai, Jie-Na [4 ]
Shu, Yi [1 ]
Tan, Jing-Yi [1 ]
Chen, Pei-Yi [1 ]
Li, Hong-Wei [5 ]
Cai, Hui-Hua [6 ]
Cai, Xiang-Sheng [3 ,7 ]
机构
[1] South China Univ Technol, Affiliated Hosp 6, Hlth Management Ctr, Sch Med, Foshan 528000, Guangdong, Peoples R China
[2] Henan Univ Chinese Med, Affiliated Hosp 1, Zhengzhou 450000, Henan, Peoples R China
[3] Univ Chinese Acad Sci, Shenzhen Hosp, Shenzhen 518001, Guangdong, Peoples R China
[4] Puning Peoples Hosp, Clin Lab, Puning 515300, Guangdong, Peoples R China
[5] Southern Med Univ, Inst Biotherapy, Guangzhou 510515, Guangdong, Peoples R China
[6] Guangdong Prov Peoples Hosp, Dept Obstet & Gynecol, Guangzhou 510080, Guangdong, Peoples R China
[7] Univ Chinese Acad Sci, Shenzhen Hosp, 4253 Songbai Rd, Shenzhen 518001, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Gut microbiome; Glucagon-like peptide-1; Gestational diabetes mellitus; Glucose; PREGNANCY; DIAGNOSIS; INSULIN;
D O I
10.4239/wjd.v13.i10.861
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Gestational diabetes mellitus (GDM) places both the mother and offspring at high risk of complications. Increasing evidence suggests that the gut microbiota plays a role in the pathogenesis of GDM. However, it is still unclear whether the gut microbiota is related to blood biochemical traits, particularly glucagon-like peptide-1 (GLP-1), in GDM patients. AIM To explore the correlation between the gut microbiota and blood biochemical traits, particularly GLP-1, in GDM patients. METHODS The V4 region of the 16S ribosomal ribonucleic acid (rRNA) gene was sequenced based on the fecal samples of 35 pregnant women with GDM and was compared to that of 25 pregnant women with normal glucose tolerance (NGT). RESULTS The results showed that Ruminococcaceae_UCG-002, Ruminococcaceae_UCG-005, Clostri-dium_sensu_stricto_1, and Streptococcus were more abundant in the NGT group than in the GDM group. Bacteroides and Lachnoclostridium were more abundant in the GDM group than in the NGT group. Spearman's correlation analysis was performed to identify the relationships between microbiota genera and blood biochemical traits. Paraprevotella, Roseburia, Faecalibacterium, and Ruminococcaceae_UCG-002 were significantly negatively correlated with glucose. Ruminococcaceae_UCG-002 was significantly negatively correlated with hemoglobin A1c. Bacteroides was significantly positively correlated with glucose. Sutterella, Oscillibacter, and Bifidobacterium were significantly positively correlated with GLP-1. A random forest model showed that 20 specific genera plus glucose provided the best discriminatory power, as indicated by the area under the receiver operating characteristic curve (0.94). CONCLUSION The results of this study reveal novel relationships between the gut microbiome, blood bio-chemical traits, particularly GLP-1, and GDM status. These findings suggest that some genera are crucial for controlling blood glucose-related indices and may be beneficial for GDM treatment. Alteration in the microbial composition of the gut may potentially serve as a marker for identifying individuals at risk of GDM.
引用
收藏
页码:861 / 876
页数:16
相关论文
共 50 条
  • [21] Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases
    Zeng, Yuan
    Wu, Yifan
    Zhang, Qian
    Xiao, Xinhua
    MBIO, 2024, 15 (01):
  • [22] Actions of glucagon-like peptide-1 receptor ligands in the gut
    Holst, Jens Juul
    Andersen, Daniel Bjorklund
    Grunddal, Kaare Villum
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (04) : 727 - 742
  • [23] Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes
    De Block, Christophe E. M.
    Dirinck, Eveline
    Verhaegen, Ann
    Van Gaal, Luc F.
    DIABETES OBESITY & METABOLISM, 2022, 24 (05): : 788 - 805
  • [24] THE EFFICACY OF TREATMENT WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN CHRONIC DIALYSIS PATIENTS WITH DIABETES MELLITUS
    Takeda, Kazuhito
    Toyonaga, Jiro
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [25] The effect of glucagon-like peptide-1 in the management of diabetes mellitus: cellular and molecular mechanisms
    Mohamed Lotfy
    Jaipaul Singh
    Hameed Rashed
    Saeed Tariq
    Erika Zilahi
    Ernest Adeghate
    Cell and Tissue Research, 2014, 358 : 343 - 358
  • [26] A Glucagon-Like Peptide-1 Receptor Agonist Lowers Weight by Modulating the Structure of Gut Microbiota
    Zhao, Li
    Chen, Yi
    Xia, Fangzhen
    Abudukerimu, Buatikamu
    Zhang, Wen
    Guo, Yuyu
    Wang, Ningjian
    Lu, Yingli
    FRONTIERS IN ENDOCRINOLOGY, 2018, 9
  • [27] Glucagon and Glucagon-like Peptide-1 Receptors: Promising Therapeutic Targets for an Effective Management of Diabetes Mellitus
    Abbas, Ghulam
    Haq, Quazi M., I
    Hamaed, Ahmad
    Al-Sibani, Mohammed
    Hussain, Hidayat
    CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (04) : 501 - 508
  • [28] Glucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus A Role in Cardiovascular Disease
    Smilowitz, Nathaniel R.
    Donnino, Robert
    Schwartzbard, Arthur
    CIRCULATION, 2014, 129 (22) : 2305 - 2312
  • [29] Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1
    Holst, JJ
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2002, 18 (06) : 430 - 441
  • [30] The effect of glucagon-like peptide-1 in the management of diabetes mellitus: cellular and molecular mechanisms
    Lotfy, Mohamed
    Singh, Jaipaul
    Rashed, Hameed
    Tariq, Saeed
    Zilahi, Erika
    Adeghate, Ernest
    CELL AND TISSUE RESEARCH, 2014, 358 (02) : 343 - 358